具有 CD38(-)CD73(-)Tim-3(-)HLA-DR(+) 表型的 CAR-T 细胞预测 tisagenlecleucel 治疗 B 细胞前体 ALL 的疗效 CAR-T cells with the CD38(-)CD73(-)Tim-3(-)HLA-DR(+) phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL. PubMed 2026/01/23 发表Cell Rep MedQ1 · IF 14(JCR 2025) 人群:儿童人群:成人靶点:CD19靶点:CD38技术:CAR-T急性淋巴细胞白血病